Escalon(R) Receives FDA 510(k) Clearance to Market the LIASYS(TM) Clinical Chemistry and Immunoturbidimetri...( Company's Fourth FDA 510(k) ...),Health

Company's Fourth FDA 510(k) Clearance Since December 2007

WAYNE, Pa., July 30 /PRNewswire-FirstCall/ -- Escalon Medical Corp. (Nasdaq: ESMC) today announced that the United States Food and Drug Administration ("FDA") has cleared the 510(k) submission for the LIASYS(TM) bench top clinical chemistry and immunoturbidimetric analyzer. The Company's recently acquired JAS Diagnostic ("JAS") unit is the distributor for the LIASYS analyzer in the United States and supplier of the associated chemistry reagents. JAS prepared and submitted the 501(k) application on behalf of the manufacturer, Analyzer Medical System, headquartered in Rome, Italy. The analyzer is being introduced at the 2008 Annual Meeting for the American Association for Clinical Chemistry ("AACC") currently being held in Washington D.C.

LIASYS is a fully automatic random access, continuous loading, easy access bench top clinical chemistry and immunoturbidimetric analyzer. The instrument features primary tubes sampling, capacitive liquid level sensing, positive identification of the samples, and module for ion selective electrode ("ISE"). It is suitable to perform the daily routine of low/medium-sized laboratories in an entirely safe and reliable way, providing flexible and cost effective solutions. The LIASYS multitasking and user-friendly software enhances the system's potential and performance.

"We believe this is an attractive chemistry analyzer that offers an excellent combination of sampling speed, precision, reliability, and ease of use," commented David Johnston, President of JAS Diagnostics. "We have optimized and validated a broad range of dedicated reagents for LIASYS and anticipate benefiting directly from an ongoing chemistry reagent revenue st
'/>"/>